tiprankstipranks
Advertisement
Advertisement

VIR Stock Latest News

Vir Biotechnology’s HBV Combo Vaccine Study Reaches Completion, Setting Up Key Pipeline Catalyst
Company AnnouncementsVir Biotechnology’s HBV Combo Vaccine Study Reaches Completion, Setting Up Key Pipeline Catalyst
19d ago
VIR
Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum
PremiumCompany Announcements
Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum
21d ago
VIR
Olema Oncology appoints Jason O’Byrne as CFO
PremiumThe Fly
Olema Oncology appoints Jason O’Byrne as CFO
22d ago
VIR
OLMA
Analyst Reiterates Buy on Vir Biotechnology, Maintains $20 Price Target Amid Strong Late-Stage HDV Momentum and Solid Cash Runway
PremiumRatings
Analyst Reiterates Buy on Vir Biotechnology, Maintains $20 Price Target Amid Strong Late-Stage HDV Momentum and Solid Cash Runway
28d ago
VIR
Vir Biotechnology: Buy Rating Reaffirmed on De-Risking HDV Franchise and Market-Building Tailwinds; $18 Price Target Unchanged
PremiumRatings
Vir Biotechnology: Buy Rating Reaffirmed on De-Risking HDV Franchise and Market-Building Tailwinds; $18 Price Target Unchanged
1M ago
VIR
Vir Biotechnology price target lowered to $25 from $27 at Morgan Stanley
PremiumThe FlyVir Biotechnology price target lowered to $25 from $27 at Morgan Stanley
1M ago
VIR
Vir Biotechnology price target lowered to $19 from $21 at Leerink
Premium
The Fly
Vir Biotechnology price target lowered to $19 from $21 at Leerink
1M ago
VIR
Analyst Reiterates Buy on Vir Biotechnology, Citing Advancing Hepatitis D and Oncology Pipelines and Strong Cash Runway
Premium
Ratings
Analyst Reiterates Buy on Vir Biotechnology, Citing Advancing Hepatitis D and Oncology Pipelines and Strong Cash Runway
1M ago
VIR
Vir Biotechnology reports Q2 EPS 47c vs. (80c) last year
PremiumThe Fly
Vir Biotechnology reports Q2 EPS 47c vs. (80c) last year
1M ago
VIR
Vir Biotechnology Names Brent Sabatini Interim Finance Chief
PremiumCompany Announcements
Vir Biotechnology Names Brent Sabatini Interim Finance Chief
2M ago
8K
VIR
Vir Biotechnology CFO Jason O’Byrne to depart
PremiumThe Fly
Vir Biotechnology CFO Jason O’Byrne to depart
2M ago
VIR
Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley
PremiumThe Fly
Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley
3M ago
VIR
MIRM
Vir Biotechnology price target raised to $27 from $23 at Morgan Stanley
PremiumThe FlyVir Biotechnology price target raised to $27 from $23 at Morgan Stanley
3M ago
VIR
MIRM
Vir Biotechnology Adds Timothy Coughlin to Board, Audit Chair
Premium
Company Announcements
Vir Biotechnology Adds Timothy Coughlin to Board, Audit Chair
3M ago
8K
VIR
Alec Stranahan Reiterates Buy on Vir Biotechnology, Sees Undervalued Pipeline with Unchanged $16 Price Target
Premium
Ratings
Alec Stranahan Reiterates Buy on Vir Biotechnology, Sees Undervalued Pipeline with Unchanged $16 Price Target
3M ago
VIR
Vir Biotechnology Announces Board Changes and Shareholder Approvals
PremiumCompany Announcements
Vir Biotechnology Announces Board Changes and Shareholder Approvals
3M ago
8K
VIR
Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial
PremiumThe Fly
Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial
4M ago
VIR
Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley
PremiumThe Fly
Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley
4M ago
VIR
Analyst Maintains Buy Rating and $20 Price Target on Vir, Citing Strengthened Oncology Franchise and Favorable Hepatitis Delta Outlook
PremiumRatings
Analyst Maintains Buy Rating and $20 Price Target on Vir, Citing Strengthened Oncology Franchise and Favorable Hepatitis Delta Outlook
4M ago
VIR
Vir Biotechnology Signals Momentum in Latest Earnings Call
PremiumCompany AnnouncementsVir Biotechnology Signals Momentum in Latest Earnings Call
4M ago
VIR
Vir Biotechnology Earns Buy Rating on Advancing Oncology and Hepatitis Delta Pipelines and Strong Cash Runway Into 2028
Premium
Ratings
Vir Biotechnology Earns Buy Rating on Advancing Oncology and Hepatitis Delta Pipelines and Strong Cash Runway Into 2028
4M ago
VIR
Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year
Premium
The Fly
Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year
4M ago
VIR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >